glp 1 logo Discover How GLP-1 Trials Are Not One-Size-Fit-All GLP-1 US

The timing is particularly relevant as Americans face what public health experts describe as a perfect storm: record obesity rates colliding with economic constraints that make proven pharmaceutical interventions financially inaccessible to average consumers

Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: An open-label, two-period, fixed-sequence, multiple-dose study

Wang, J., Yadav, V., Smart, A

Owing to their effectiveness in reducing body weight, once-daily subcutaneous administration of liraglutide 3.0 mg has been approved, and once-weekly subcutaneous administration of semaglutide 2.4 mg is being investigated in phase III trials, for obesity management